The Potential Markers of Circulating microRNAs and long non-coding RNAs in Alzheimer's Disease

Alzheimer's disease (AD) is a neurodegenerative disorder and one of the leading causes of disability and mortality in the late life with no curative treatment currently. Thus, it is urgently to establish sensitive and non-invasive biomarkers for AD diagnosis, particularly in the early stage. Re...

Full description

Saved in:
Bibliographic Details
Published in:Aging and disease 2019-12, Vol.10 (6), p.1293-1301
Main Authors: Zhao, Yanfang, Zhang, Yuan, Zhang, Lei, Dong, Yanhan, Ji, Hongfang, Shen, Liang
Format: Article
Language:English
Subjects:
Advertising executives
Alzheimer's disease
Biological markers
Disabilities
Diseases
Enzymes
Health aspects
MicroRNA
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer's disease (AD) is a neurodegenerative disorder and one of the leading causes of disability and mortality in the late life with no curative treatment currently. Thus, it is urgently to establish sensitive and non-invasive biomarkers for AD diagnosis, particularly in the early stage. Recently, emerging number of microRNAs (miRNAs) and long-noncoding RNAs (lncRNAs) are considered as effective biomarkers in various diseases as they possess characteristics of stable, resistant to RNAase digestion and many extreme conditions in circulatory fluid. This review highlights recent advances in the identification of the aberrantly expressed miRNAs and lncRNAs in circulatory network for detection of AD. We summarized the abnormal expressed miRNAs in blood and cerebrospinal fluid (CSF), and detailed discussed the functions and molecular mechanism of serum or plasma miRNAs-miR-195, miR-155, miR-34a, miR-9, miR-206, miR-125b and miR-29 in the regulation of AD progression. In addition, we also elaborated the role of circulating lncRNA major including beta-site APP cleaving enzyme 1 (BACE1) and its antisense lncRNA BACE1-AS in AD pathological advancement. In brief, confirming the aberrantly expressed circulating miRNAs and lncRNAs will provide an effective testing tools for treatment of AD in the future. Key words: Alzheimer's disease, circulating, miRNA, lncRNA
ISSN:2152-5250
2152-5250
DOI:10.14336/AD.2018.1105